Cost-Effectiveness of the 21-Gene Breast Cancer Assay in Mexico
Conclusion
In early-stage breast cancer patients in Mexico, guiding decision making on adjuvant therapy using the 21-gene assay was projected to improve life expectancy in comparison with the current standard of care, with an ICER of MXN 25,244 (USD 1914) per life-year gained, which is within the range generally considered cost-effective.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Genetics | Health | Hormonal Therapy | Hormones | Mexico Health